These were the biggest pharmaceutical deals in early 2022
GlobalData tracks the latest acquisitions, mergers, venture financing and asset transactions in the pharmaceutical sector.
By
Deals
Latest in
Deals
Taiho signs deal to acquire Cullinan Pearl for up to $405m
On Taiho acquiring Cullinan Pearl, Cullinan Oncology is entitled to receive $275m in upfront payment.
BridgeBio and BMS partner to develop BBP-398 for cancer
Under the deal, BMS will make upfront and milestone payments of up to $905m to BridgeBio.
AnGes and Eiger collaborate to distribute Zokinvy in Japan
AnGes will make upfront and milestone payments up to $1.5m to Eiger, under the deal.
Pfizer to acquire Biohaven Pharmaceutical for $11.6bn in cash
According to the deal, Pfizer will acquire CGRP programmes of Biohaven, including rimegepant, zavegepant and five pre-clinical assets.
API and University of Waterloo to develop coronavirus drugs
This alliance is the third academic-industry partnership of API this year to develop therapies against viral variants.
Top and emerging locations for M&A deals in the pharmaceutical industry
The data shows that M&A activity is strongest in the US, which saw a total of 19 deals announced in…
By
Twist Bioscience and Astellas to develop tumour-targeting antibodies
Astellas will handle the development, production and marketing of any licenced products developed out of the partnership.